Pharma: Other news to note
Helsinn Group, of Lugano, Switzerland, and Eisai Inc., of Woodcliff Lake, N.J., said the FDA accepted for review the submission of the new drug application for the investigational oral fixed-dose combination capsule of netupitant 300 mg + palonosetron 0.50 mg for prevention of acute and delayed chemotherapy-induced nausea and vomiting following highly and moderately emetogenic chemotherapy.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.